Patients with TNBC have worse survival than patients with non-TNBC. The new AJCC staging manual should consider breast cancer biomarker information.

Patients with tumors that are ER-positive 1%-9% have clinical and pathologic characteristics different from those with tumors that are ER-positive ≥10%. Similar to patients with ER-negative tumors, those with ER-positive 1%-9% disease do not appear to benefit from endocrine therapy; further study of its clinical benefit in this group is warranted. Also, there is a need to better define which patients of this group belong to basal or luminal subtypes.

No abstract

In vitro studies have implicated nuclear respiratory factor 1 (NRF-1) in the transcriptional expression of nuclear genes required for mitochondrial respiratory function, as well as for other fundamental cellular activities. We investigated here the in vivo function of NRF-1 in mammals by disrupting the gene in mice. A portion of the NRF-1 gene that encodes the nuclear localization signal and the DNA-binding and dimerization domains was replaced through homologous recombination by a ␤-galactosidase-neomycin cassette. In the mutant allele, ␤-galactosidase expression is under the control of the NRF-1 promoter. Embryos homozygous for NRF-1 disruption die between embryonic days 3.5 and 6.5. ␤-Galactosidase staining was observed in growing oocytes and in 2.5-and 3.5-day-old embryos, demonstrating that the NRF-1 gene is expressed during oogenesis and during early stages of embryogenesis. Moreover, the embryonic expression of NRF-1 did not result from maternal carryover. While most isolated wild-type and NRF-1 ؉/؊ blastocysts can develop further in vitro, the NRF-1 ؊/؊ blastocysts lack this ability despite their normal morphology. Interestingly, a fraction of the blastocysts from heterozygous matings had reduced staining intensity with rhodamine 123 and NRF-1 ؊/؊ blastocysts had markedly reduced levels of mitochondrial DNA (mtDNA). The depletion of mtDNA did not coincide with nuclear DNA fragmentation, indicating that mtDNA loss was not associated with increased apoptosis. These results are consistent with a specific requirement for NRF-1 in the maintenance of mtDNA and respiratory chain function during early embryogenesis.The electron transport and oxidative phosphorylation system in mammalian mitochondria requires contributions from both the nuclear and the mitochondrial genetic systems. The mitochondrial DNA encodes 13 respiratory subunits, as well as the 22 tRNAs and 2 rRNAs required for their mitochondrial translation. However, most respiratory proteins and all of the gene products required for mitochondrial DNA (mtDNA) replication and transcription are nucleus encoded (reviewed in references 39 and 42). Nuclear respiratory factor 1 (NRF-1) was identified as a nuclear transcription factor that transactivates the promoters of a number of mitochondrion-related genes in vitro (7,10,11,48). These include respiratory subunits, the rate-limiting heme biosynthetic enzyme, and factors involved in the replication and transcription of mtDNA (reviewed in reference 39). Among the most intriguing is TFAM, a nucleus-encoded transcription factor that acts on bidirectional promoters within the mitochondrial D-loop regulatory region (12). TFAM was recently shown to be essential for mitochondrial biogenesis during embryonic development (29) and for normal function of the heart (50). Moreover, NRF-1 is involved in the transcriptional control of mitochondrial biogenesis during adaptive thermogenesis through its interaction with the cold-inducible coactivator PGC-1 (53).In addition to its proposed role in respiratory chain expression, ...

No abstract

Melatonin has beneficial effects against early brain injury (EBI) by modulating cerebral oxidative stress after experimental subarachnoid hemorrhage (SAH); however, few investigations relate to the precise underlying molecular mechanisms. To date, the relation between melatonin and nuclear factor erythroid 2-related factor 2 and antioxidant responsive element (Nrf2-ARE) pathway has not been studied in SAH models. This study was undertaken to evaluate the influence of melatonin on Nrf2-ARE pathway in rats after SAH. Adult male SD rats were divided into four groups: (i) control group (n=18); (ii) SAH group (n=18); (iii) SAH+vehicle group (n=18); and (iv) SAH+melatonin group (n=18). The rat SAH model was induced by injection of 0.3mL fresh arterial, nonheparinized blood into the prechiasmatic cistern in 20s. In SAH+melatonin group, melatonin was administered i.p. at 150mg/kg at 2 and 24hr after the induction of SAH. Brain samples were extracted at 48hr after SAH. Treatment with melatonin markedly increased the expressions of Nrf2-ARE pathway-related agents, such as Nrf2, heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, and glutathione S-transferase α-1. Administration of melatonin following SAH significantly ameliorated EBI, including brain edema, blood-brain barrier (BBB) impairment, cortical apoptosis, and neurological deficits. In conclusion, post-SAH melatonin administration may attenuate EBI in this SAH model, possibly through activating Nrf2-ARE pathway and modulating cerebral oxidative stress by inducing antioxidant and detoxifying enzymes.

Breast cancer brain metastasis is resistant to therapy and a particularly poor prognostic feature in patient survival. Altered metabolism is a common feature of cancer cells but little is known as to what metabolic changes benefit breast cancer brain metastases. We found that brain-metastatic breast cancer cells evolved the ability to survive and proliferate independent of glucose due to enhanced gluconeogenesis and oxidations of glutamine and branched chain amino acids, which together sustain the non-oxidative pentose pathway for purine synthesis. Silencing expression of fructose-1,6-bisphosphatases (FBPs) in brain metastatic cells reduced their viability and improved the survival of metastasis-bearing immunocompetent hosts. Clinically, we showed that brain metastases from human breast cancer patients expressed higher levels of FBP and glycogen than the corresponding primary tumors. Together, our findings identify a critical metabolic condition required to sustain brain metastasis, and suggest that targeting gluconeogenesis may help eradicate this deadly feature in advanced breast cancer patients.

Porous and single crystalline ZnO nanosheets, which were synthesized by annealing hydrozincite Zn(5)(CO(3))(2)(OH)(6) nanoplates produced with a water/ethylene glycol solvothermal method, are used as building blocks to construct functional Pd-ZnO nanoarchitectures together with Pd nanoparticles based on a self-assembly approach. Chemical sensing performances of the ZnO nanosheets were investigated carefully before and after their surface modification with Pd nanoparticles. It was found that the chemical sensors made with porous ZnO nanosheets exhibit high selectivity and quick response for detecting acetone, because of the 2D ZnO nanocrystals exposed in (100) facets at high percentage. The performances of the acetone sensors can be further improved dramatically, after the surfaces of ZnO nanosheets are modified with Pd nanoparticles. Novel acetone sensors with enhanced response, selectivity and stability have been fabricated successfully by using nanoarchitectures consisting of ZnO nanosheets and Pd nanoparticles.